Trial Profile
A Study Of Combination Chemotherapy And Surgical Resection In The Treatment Of Adrenocortical Cancer: Mitotane And Continuous Infusion Doxorubicin, Vincristine And Etoposide With The P-Glycoprotein Antagonist, Tariquidar (XR9576), Before And After Surgical Resection.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Tariquidar (Primary) ; Doxorubicin; Etoposide; Mitotane; Vincristine
- Indications Adrenal cancer
- Focus Therapeutic Use
- 27 Feb 2012 Actual initiation date changed from Dec 2004 to Oct 2003 as reported by ClinicalTrials.gov.
- 27 Feb 2012 Actual initiation date changed from Dec 2004 to Oct 2003 as reported by ClinicalTrials.gov.
- 27 Feb 2012 Planned number of patients changed from 50 to 47 as reported by ClinicalTrials.gov.